TP53 Mutation Is a Prognostic Factor in Lower Grade Glioma and May Influence Chemotherapy Efficacy

The Hippo Signaling Pathway in Drug Resistance in Cancer

(2021) Renya Zeng et al.   Cancers

Sanger sequencing is no longer always necessary based on a single-center validation of 1109 NGS variants in 825 clinical exomes

(2021) A. Arteche-López et al.   Scientific Reports

Phase I study of a brain penetrant mutant IDH1 inhibitor DS-1001b in patients with recurrent or progressive IDH1 mutant gliomas.

(2019) Atsushi Natsume et al.   JOURNAL OF CLINICAL ONCOLOGY

Genomic correlates of disease progression and treatment response in prospectively characterized gliomas

(2019) Philip Jonsson et al.   CLINICAL CANCER RESEARCH

Reciprocal Crosstalk Between YAP1/Hippo Pathway and the p53 Family Proteins: Mechanisms and Outcomes in Cancer

(2019) Nitin Raj et al.   Frontiers in Cell and Developmental Biology

396PDCharacterization of a novel BBB-permeable mutant IDH1 inhibitor, DS-1001b

(2019) H Matsunaga et al.   ANNALS OF ONCOLOGY

Metabolic profiling of human gliomas assessed with NMR

(2019) Jung Eun Lee et al.   JOURNAL OF CLINICAL NEUROSCIENCE

The TCGA Legacy

(2018)   CELL

Fatal correlation between YAP1 expression and glioma aggressiveness: clinical and molecular evidence

(2018) Pierre-Olivier Guichet et al.   JOURNAL OF PATHOLOGY

Awakening the “guardian of genome”: reactivation of mutant p53

(2018) Akshay Binayke et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

TP53 mutations as potential prognostic markers for specific cancers: analysis of data from The Cancer Genome Atlas and the International Agency for Research on Cancer TP53 Database

(2018) Victor D. Li et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Point mutations in the DNA binding domain of p53 contribute to glioma progression and poor prognosis

(2017) P. P. Sarma et al.   MOLECULAR BIOLOGY

ACTR-46. AG-120, A FIRST-IN-class MUTANT IDH1 INHIBITOR IN PATIENTS WITH RECURRENT OR PROGRESSIVE IDH1 MUTANT GLIOMA: UPDATED RESULTS FROM THE PHASE 1 NON-ENHANCING GLIOMA POPULATION

(2017) Ingo K Mellinghoff et al.   NEURO-ONCOLOGY

EZH2-, CHD4-, and IDH-linked epigenetic perturbation and its association with survival in glioma patients

(2017) Le Zhang et al.   Journal of Molecular Cell Biology

Discovery and Evaluation of Clinical Candidate IDH305, a Brain Penetrant Mutant IDH1 Inhibitor

(2017) Young Shin Cho et al.   ACS Medicinal Chemistry Letters

A Brain Penetrant Mutant IDH1 Inhibitor Provides In Vivo Survival Benefit

(2017) Johnny Kopinja et al.   Scientific Reports

The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary

(2016) David N. Louis et al.   ACTA NEUROPATHOLOGICA

Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma

(2016) Michele Ceccarelli et al.   CELL

Emerging targeted therapies for glioma

(2016) Julie J Miller et al.   EXPERT OPINION ON EMERGING DRUGS

MicroRNA profiling of low-grade glial and glioneuronal tumors shows an independent role for cluster 14q32.31 member miR-487b

(2016) Heather Marion Ames et al.   MODERN PATHOLOGY

Multi-platform molecular profiling of a large cohort of glioblastomas reveals potential therapeutic strategies

(2016) Joanne Xiu et al.   Oncotarget

Classifying lower grade glioma cases according to whole genome gene expression

(2016) Baoshi Chen et al.   Oncotarget

Treatment Strategies for Low-Grade Glioma in Adults

(2016) Nancy Ann Oberheim Bush et al.   Journal of Oncology Practice

TP53 mutational status is predictive of pazopanib response in advanced sarcomas

(2015) K. Koehler et al.   ANNALS OF ONCOLOGY

Prognostic Value of MGMT Promoter Methylation and TP53 Mutation in Glioblastomas Depends on IDH1 Mutation

(2015) Kai Wang et al.   Asian Pacific Journal of Cancer Prevention

YAP enhances the pro‐proliferative transcriptional activity of mutant p53 proteins

(2015) Silvia Di Agostino et al.   EMBO REPORTS

Survival and low-grade glioma: the emergence of genetic information

(2015) Elizabeth B. Claus et al.   Neurosurgical Focus

Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas

(2015)   NEW ENGLAND JOURNAL OF MEDICINE

RevisitingTP53Mutations and Immunohistochemistry-A Comparative Study in 157 Diffuse Gliomas

(2014) Hirokazu Takami et al.   BRAIN PATHOLOGY

c-Abl antagonizes the YAP oncogenic function

(2014) R Keshet et al.   CELL DEATH AND DIFFERENTIATION

TP63 and TP73 in cancer, an unresolved “family” puzzle of complexity, redundancy and hierarchy

(2014) Antonio Costanzo et al.   FEBS LETTERS

How theTP53Family ProteinsTP63andTP73Contribute to Tumorigenesis: Regulators and Effectors

(2014) Eleonora Candi et al.   HUMAN MUTATION

TP53 and p53 statuses and their clinical impact in diffuse low grade gliomas

(2014) Emeline Gillet et al.   JOURNAL OF NEURO-ONCOLOGY

Localizing seizure-susceptible brain regions associated with low-grade gliomas using voxel-based lesion-symptom mapping

(2014) Yinyan Wang et al.   NEURO-ONCOLOGY

Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool

(2013) Edward Y Chen et al.   BMC BIOINFORMATICS

Yes-associated protein (YAP) increases chemosensitivity of hepatocellular carcinoma cells by modulation of p53

(2013) Nan Bai et al.   CANCER BIOLOGY & THERAPY

Clinical value of chromosome arms 19q and 11p losses in low-grade gliomas

(2013) Agustí Alentorn et al.   NEURO-ONCOLOGY

Expression of p53, epidermal growth factor receptor, Ki-67 and O6-methylguanine-DNA methyltransferase in human gliomas

(2013) XINHUA HU et al.   Oncology Letters

Temozolomide suppresses MYC via activation of TAp63 to inhibit progression of human glioblastoma

(2013) Tomohiro Yamaki et al.   Scientific Reports

Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations

(2012) Xiao-Yang Liu et al.   ACTA NEUROPATHOLOGICA

SnapShot: The Hippo Signaling Pathway

(2011) Caroline Badouel et al.   CELL

Molecular Markers in Low-Grade Gliomas: Predictive or Prognostic?

(2011) C. Hartmann et al.   CLINICAL CANCER RESEARCH

IDH1 and IDH2 mutations, immunohistochemistry and associations in a series of brain tumors

(2011) Marta Mellai et al.   JOURNAL OF NEURO-ONCOLOGY

Molecular Classification of Low-Grade Diffuse Gliomas

(2010) Young-Ho Kim et al.   AMERICAN JOURNAL OF PATHOLOGY

The Hippo Signaling Pathway in Development and Cancer

(2010) Duojia Pan   DEVELOPMENTAL CELL

MGMT promoter hypermethylation is a frequent, early, and consistent event in astrocytoma progression, and not correlated with TP53 mutation

(2010) Floris H. Groenendijk et al.   JOURNAL OF NEURO-ONCOLOGY

Effect of aberrant p53 function on temozolomide sensitivity of glioma cell lines and brain tumor initiating cells from glioblastoma

(2010) Michael D. Blough et al.   JOURNAL OF NEURO-ONCOLOGY

All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2

(2010) M. Labussiere et al.   NEUROLOGY

The p53 Family Protein p73 Provides New Insights into Cancer Chemosensitivity and Targeting

(2009) P. Lunghi et al.   CLINICAL CANCER RESEARCH

IDH1andIDH2Mutations in Gliomas

(2009) Hai Yan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical Outcomes and Correlates of TP53 Mutations and Cancer

(2009) A. I. Robles et al.   Cold Spring Harbor Perspectives in Biology

PML, YAP, and p73 Are Components of a Proapoptotic Autoregulatory Feedback Loop

(2008) Eleonora Lapi et al.   MOLECULAR CELL

Malignant Gliomas in Adults

(2008) Patrick Y. Wen et al.   NEW ENGLAND JOURNAL OF MEDICINE

An Integrated Genomic Analysis of Human Glioblastoma Multiforme

(2008) D. W. Parsons et al.   SCIENCE